Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab monotherapy for macular edema secondary to retinal vein occlusion (Japan, phase III)
jRCT2080221503Phase 3
- Sponsor
- Novartis
- Start
- Jul 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in branch retinal vein occlusion (BRVO) and central retinal vein occlusion with macular edema, sponsored by Novartis.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)central retinal vein occlusion with macular edema
Beyond the preview
Go deeper on jRCT2080221503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221503.